No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair
Launched by CLAYTON PETRO · Jul 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying pain management after a common surgery called inguinal hernia repair. Researchers want to find out if patients can manage their pain without taking opioids, which are strong pain medications that can be addictive. Specifically, they are comparing two groups: one group will receive no opioids after surgery, while the other group will receive a small amount of opioids. The goal is to see if those who don’t take opioids will need fewer refills for pain medication and if their quality of life after surgery is similar to those who do take opioids.
To be eligible for this trial, participants must be at least 18 years old and scheduled for an elective inguinal hernia repair surgery. They should be able to tolerate general anesthesia, which is a type of medication used to keep patients asleep during surgery. However, people who have chronic pain and are taking opioids regularly, or those who cannot handle general anesthesia or pain medications, will not be included. If you choose to participate, you will be monitored for 30 days after your surgery to assess your pain levels and overall recovery. This trial aims to find safer pain management options for patients after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged 18 years or older
- • Patients undergoing elective unilateral or bilateral inguinal hernia repairs
- • Patients able to tolerate general anesthesia
- Exclusion Criteria:
- • Patients who cannot tolerate general anesthesia,
- • Patients who cannot tolerate opioids or NSAIDS,
- • Patients on opioids for chronic pain management (defined as near daily use within 90 days),
- • Patients who undergo surgeries requiring extensive dissection/hernia sac reduction, or additional procedures,
- • Patients requiring inpatient admission postoperatively
- • Patients who are not able to understand and sign a written consent form
About Clayton Petro
Clayton Petro is a leading clinical trial sponsor dedicated to advancing medical research and innovation through the development of novel therapies. With a strong focus on improving patient outcomes, Clayton Petro collaborates with healthcare professionals, regulatory bodies, and research institutions to design and execute high-quality clinical trials across various therapeutic areas. Their commitment to ethical practices and rigorous scientific standards ensures the integrity of their research, while their experienced team of professionals works diligently to bring groundbreaking treatments to market, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milwaukee, Wisconsin, United States
Knoxville, Tennessee, United States
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Fountain Valley, California, United States
Royal Oak, Michigan, United States
Patients applied
Trial Officials
Clayton C Petro, MD
Principal Investigator
The Cleveland Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported